Olatec Therapeutics, LLC
Olatec is a biopharmaceutical company dedicated to improving health through the development of safe and effective pharmaceuticals targeting inflammatory diseases. They focus on NLRP3 inflammasome inhibitors, with their lead compound dapansutrile (OLT1177®), which has shown clinical benefits in various inflammatory conditions. The company conducts operations in the US and Europe, with a team of experienced management and thought leaders in inflammation and immunology.
Industries
Nr. of Employees
small (1-50)
Olatec Therapeutics, LLC
Products
Dapansutrile (selective NLRP3 inhibitor)
Oral small-molecule inhibitor that selectively targets NLRP3 to prevent inflammasome formation and reduce production of IL-1β and IL-18; advanced clinical-stage candidate being evaluated in multiple inflammatory indications.
Dapansutrile (selective NLRP3 inhibitor)
Oral small-molecule inhibitor that selectively targets NLRP3 to prevent inflammasome formation and reduce production of IL-1β and IL-18; advanced clinical-stage candidate being evaluated in multiple inflammatory indications.
Services
Clinical development and trial execution
Design and conduct of early-phase human studies (safety, pharmacodynamics, proof-of-concept) using randomized, dose-escalation and dose-adaptive methodologies.
Preclinical pharmacology and efficacy testing
Preclinical efficacy studies in multiple disease models to assess target engagement, functional protection and disease-modifying potential.
Medicinal chemistry and analogue development
Synthesis and early screening of structurally related compound series to optimize potency, selectivity and drug-like properties.
Regulatory dossier preparation and strategy
Regulatory planning and document preparation informed by team experience drafting IND/NDA/BLA/MAA-style submissions and interacting with regulatory agencies.
Clinical development and trial execution
Design and conduct of early-phase human studies (safety, pharmacodynamics, proof-of-concept) using randomized, dose-escalation and dose-adaptive methodologies.
Preclinical pharmacology and efficacy testing
Preclinical efficacy studies in multiple disease models to assess target engagement, functional protection and disease-modifying potential.
Medicinal chemistry and analogue development
Synthesis and early screening of structurally related compound series to optimize potency, selectivity and drug-like properties.
Regulatory dossier preparation and strategy
Regulatory planning and document preparation informed by team experience drafting IND/NDA/BLA/MAA-style submissions and interacting with regulatory agencies.
Expertise Areas
- Small-molecule drug discovery for innate immunity targets
- Preclinical disease-model evaluation
- Early-phase clinical trial management
- Translational pharmacology and biomarker development
Key Technologies
- NLRP3 inflammasome inhibition
- Small-molecule medicinal chemistry
- Animal disease models (murine)
- Cytokine biomarker assays (IL-1β, IL-18)